DYN
Price
$14.22
Change
+$0.98 (+7.40%)
Updated
Sep 5 closing price
Capitalization
1.88B
54 days until earnings call
RNA
Price
$50.36
Change
+$1.89 (+3.90%)
Updated
Sep 5 closing price
Capitalization
6.48B
66 days until earnings call
Interact to see
Advertisement

DYN vs RNA

Header iconDYN vs RNA Comparison
Open Charts DYN vs RNABanner chart's image
Dyne Therapeutics
Price$14.22
Change+$0.98 (+7.40%)
Volume$2.42M
Capitalization1.88B
Avidity Biosciences
Price$50.36
Change+$1.89 (+3.90%)
Volume$7.39M
Capitalization6.48B
DYN vs RNA Comparison Chart in %
Loading...
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DYN vs. RNA commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYN is a StrongBuy and RNA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (DYN: $14.22 vs. RNA: $50.36)
Brand notoriety: DYN and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYN: 81% vs. RNA: 154%
Market capitalization -- DYN: $1.88B vs. RNA: $6.48B
DYN [@Biotechnology] is valued at $1.88B. RNA’s [@Biotechnology] market capitalization is $6.48B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYN’s FA Score shows that 1 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • DYN’s FA Score: 1 green, 4 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, both DYN and RNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYN’s TA Score shows that 3 TA indicator(s) are bullish while RNA’s TA Score has 4 bullish TA indicator(s).

  • DYN’s TA Score: 3 bullish, 3 bearish.
  • RNA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, DYN is a better buy in the short-term than RNA.

Price Growth

DYN (@Biotechnology) experienced а +5.41% price change this week, while RNA (@Biotechnology) price change was +8.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

DYN is expected to report earnings on Oct 30, 2025.

RNA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($6.48B) has a higher market cap than DYN($1.88B). RNA YTD gains are higher at: 73.177 vs. DYN (-39.643). DYN has higher annual earnings (EBITDA): -437.37M vs. RNA (-518.74M). RNA has more cash in the bank: 1.18B vs. DYN (684M). RNA has less debt than DYN: RNA (5.14M) vs DYN (121M). RNA has higher revenues than DYN: RNA (10.7M) vs DYN (0).
DYNRNADYN / RNA
Capitalization1.88B6.48B29%
EBITDA-437.37M-518.74M84%
Gain YTD-39.64373.177-54%
P/E RatioN/AN/A-
Revenue010.7M-
Total Cash684M1.18B58%
Total Debt121M5.14M2,356%
TECHNICAL ANALYSIS
Technical Analysis
DYNRNA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 10 days ago
85%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 24 days ago
86%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PVFAX57.70N/A
N/A
Paradigm Value
DODWX16.13N/A
N/A
Dodge & Cox Global Stock I
NFALX35.49N/A
N/A
Neuberger Berman Focus I
OSCYX23.88N/A
N/A
Invesco Main Street Small Cap Y
VPRDX13.79N/A
N/A
VY® Morgan Stanley Global Franchise R6